Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers

References

• Anttila, S. A. K., & Leinonen, E. V. J. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews, 7(3), 249–264. https://doi.org/10.1111/j.1527-3458.2001.tb00198.x
   PubMedGoogle Scholar
• Basterzi, A. D., Aydemir, Ç., Kisa, C., Aksaray, S., Tuzer, V., Yazici, K., & Göka, E. (2005). IL-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacology, 20(7), 473–476. https://doi.org/10.1002/hup.717
   PubMed Web of Science ®Google Scholar
• Bech, P. (2006). Rating scales in depression: Limitations and pitfalls. Dialogues in Clinical Neuroscience, 8(2), 207–215. https://doi.org/10.31887/DCNS.2006.8.2/pbech
   PubMedGoogle Scholar
• Beurel, E., Toups, M., & Nemeroff, C. B. (2020). The bidirectional relationship of depression and inflammation: Double trouble. Neuron, 107(2), 234–256. https://doi.org/10.1016/j.neuron.2020.06.002
   PubMed Web of Science ®Google Scholar
• Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009). Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology, 19(7), 457–465. https://doi.org/10.1016/j.euroneuro.2009.01.015
   PubMed Web of Science ®Google Scholar
• Burcusa, S. L., & Iacono, W. G. (2007). Risk for recurrence in depression. Clinical Psychology Review, 27(8), 959–985. https://doi.org/10.1016/j.cpr.2007.02.005
   PubMed Web of Science ®Google Scholar
• de Berardis, D., Conti, C. M. V., Serroni, N., Moschetta, F. S., Olivieri, L., Carano, A., Salerno, R. M., Cavuto, M., Farina, B., Alessandrini, M., Janiri, L., Pozzi, G., & di Giannantonio, M. (2010). The effect of newer serotonin-noradrenalin antidepressants on cytokine production: A review of the current literature. International Journal of Immunopathology and Pharmacology, 23(2), 417–422. https://doi.org/10.1177/039463201002300204
   PubMed Web of Science ®Google Scholar
• Deecher, D. C., Beyer, C. E., Johnston, G., Bray, J., Shah, S., Abou-Gharbia, M., & Andree, T. H. (2006). Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 318(2), 657–665. https://doi.org/10.1124/jpet.106.103382
   PubMed Web of Science ®Google Scholar
• Fava, M., & Rush, A. J. (2006). Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychotherapy and Psychosomatics, 75(3), 139–153. https://doi.org/10.1159/000091771
   PubMed Web of Science ®Google Scholar
• Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 21(12), 1696–1709. https://doi.org/10.1038/mp.2016.3
   PubMed Web of Science ®Google Scholar
• Gonul, A. S., Akdeniz, F., Donat, O., & Vahip, S. (2003). Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: Four cases. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27(5), 889–891. https://doi.org/10.1016/S0278-5846(03)00120-9
   PubMed Web of Science ®Google Scholar
• Gupta, K., Gupta, R., Bhatia, M. S., Tripathi, A. K., & Gupta, L. K. (2017). Effect of agomelatine and fluoxetine on HAM-D score, serum brain-derived neurotrophic factor, and tumor necrosis factor-α level in patients with major depressive disorder with severe depression. Journal of Clinical Pharmacology, 57(12), 1519–1526. https://doi.org/10.1002/jcph.963
   PubMed Web of Science ®Google Scholar
• Gupta, R., Gupta, K., Tripathi, A. K., Bhatia, M. S., & Gupta, L. K. (2016). Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-α in patients of major depressive disorder with severe depression. Pharmacology, 97(3-4), 184–188. https://doi.org/10.1159/000444220
   PubMed Web of Science ®Google Scholar
• Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022). Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression. JAMA Psychiatry, 79(4), 300–312. https://doi.org/10.1001/jamapsychiatry.2021.4313
   PubMed Web of Science ®Google Scholar
• Hock, R. S., Or, F., Kolappa, K., Burkey, M. D., Surkan, P. J., & Eaton, W. W. (2012). A new resolution for global mental health. Lancet (London, England), 379(9824), 1367–1368. https://doi.org/10.1016/S0140-6736(12)60243-8
   PubMed Web of Science ®Google Scholar
• Judd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000). Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? The American Journal of Psychiatry, 157(9), 1501–1504. https://doi.org/10.1176/appi.ajp.157.9.1501
   PubMed Web of Science ®Google Scholar
• Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018). Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry, 23(2), 335–343. https://doi.org/10.1038/mp.2016.167
   PubMed Web of Science ®Google Scholar
• Karlović, D., Serretti, A., Vrkić, N., Martinac, M., & Marčinko, D. (2012). Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Research, 198(1), 74–80. https://doi.org/10.1016/j.psychres.2011.12.007
   PubMed Web of Science ®Google Scholar
• Kato, T., Furukawa, T. A., Mantani, A., Kurata, K., Kubouchi, H., Hirota, S., Sato, H., Sugishita, K., Chino, B., Itoh, K., Ikeda, Y., Shinagawa, Y., Kondo, M., Okamoto, Y., Fujita, H., Suga, M., Yasumoto, S., Tsujino, N., Inoue, T., … Guyatt, G. H, for the SUN☺D Investigators. (2018). Optimising first- and second-line treatment strategies for untreated major depressive disorder—the SUN☺D study: A pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Medicine, 16(1), 103. https://doi.org/10.1186/s12916-018-1096-5
   PubMedGoogle Scholar
• Kennedy, S. H. (2008). Core symptoms of major depressive disorder: Relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience, 10(3), 271–277. https://doi.org/10.31887/DCNS.2008.10.3/shkennedy
   PubMedGoogle Scholar
• Leonard, B., & Maes, M. (2012). Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neuroscience and Biobehavioral Reviews, 36(2), 764–785. https://doi.org/10.1016/j.neubiorev.2011.12.005
   PubMed Web of Science ®Google Scholar
• Li, Z., Qi, D., Chen, J., Zhang, C., Yi, Z., Yuan, C., Wang, Z., Hong, W., Yu, S., Cui, D., & Fang, Y. (2013). Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: A prospective longitudinal study. Psychoneuroendocrinology, 38(1), 107–114. https://doi.org/10.1016/j.psyneuen.2012.05.005
   PubMed Web of Science ®Google Scholar
• Lieberman, D. Z., & Massey, S. H. (2009). Desvenlafaxine in major depressive disorder: An evidence-based review of its place in therapy. Core Evidence, 4, 67–82. https://doi.org/10.2147/CE.S5998
   Google Scholar
• Lin, C.-H., Chen, C.-C., Wang, F.-C., & Lane, H.-Y. (2013). Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission. Psychiatry and Clinical Neurosciences, 67(4), 265–272. https://doi.org/10.1111/pcn.12046
   PubMed Web of Science ®Google Scholar
• Makhija, K., & Karunakaran, S. (2013). The role of inflammatory cytokines on the aetiopathogenesis of depression. The Australian and New Zealand Journal of Psychiatry, 47(9), 828–839. https://doi.org/10.1177/0004867413488220
   PubMed Web of Science ®Google Scholar
• Melfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998). The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry, 55(12), 1128–1132. https://doi.org/10.1001/archpsyc.55.12.1128
   PubMed Web of Science ®Google Scholar
• Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013). Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depression and Anxiety, 30(4), 297–306. https://doi.org/10.1002/da.22084
   PubMed Web of Science ®Google Scholar
• Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry, 63(4), 424–434. https://doi.org/10.1016/j.biopsych.2007.06.027
   PubMed Web of Science ®Google Scholar
• Pizzi, C., Mancini, S., Angeloni, L., Fontana, F., Manzoli, L., & Costa, G. M. (2009). Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics, 86(5), 527–532. https://doi.org/10.1038/clpt.2009.121
   PubMed Web of Science ®Google Scholar
• Reddy, M. S. (2010). Depression: The disorder and the burden. Indian Journal of Psychological Medicine, 32(1), 1–2. https://doi.org/10.4103/0253-7176.70510
   PubMedGoogle Scholar
• Rocha, F. L., Fuzikawa, C., Riera, R., & Hara, C. (2012). Combination of antidepressants in the treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 32(2), 278–281. https://doi.org/10.1097/JCP.0b013e318248581b
   PubMed Web of Science ®Google Scholar
• Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., Cook, I. A., Shelton, R. C., Lesser, I. M., Kornstein, S. G., & Wisniewski, S. R. (2011). Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. The American Journal of Psychiatry, 168(7), 689–701. https://doi.org/10.1176/appi.ajp.2011.10111645
   PubMed Web of Science ®Google Scholar
• Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline. International Clinical Psychopharmacology, 29(4), 185–196. https://doi.org/10.1097/YIC.0000000000000023
   PubMed Web of Science ®Google Scholar
• Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015). Inflammation and clinical response to treatment in depression: A meta-analysis. European Neuropsychopharmacology, 25(10), 1532–1543. https://doi.org/10.1016/j.euroneuro.2015.06.007
   PubMed Web of Science ®Google Scholar
• Tafseer, S., Gupta, R., Ahmad, R., Jain, S., Bhatia, M. S., & Gupta, L. K. (2021). Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder. Pharmacology, Biochemistry, and Behavior, 200, 173073. https://doi.org/10.1016/j.pbb.2020.173073
   PubMed Web of Science ®Google Scholar
• Taraz, M., Khatami, M.-R., Dashti-Khavidaki, S., Akhonzadeh, S., Noorbala, A.-A., Ghaeli, P., & Taraz, S. (2013). Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial. International Immunopharmacology, 17(3), 917–923. https://doi.org/10.1016/j.intimp.2013.09.020
   PubMed Web of Science ®Google Scholar
• Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., Shores-Wilson, K., Biggs, M. M., Balasubramani, G. K., & Fava, M, STAR*D Study Team. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. The American Journal of Psychiatry, 163(1), 28–40. https://doi.org/10.1176/appi.ajp.163.1.28
   PubMed Web of Science ®Google Scholar
• Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology, 170(4), 429–433. https://doi.org/10.1007/s00213-003-1566-z
   PubMed Web of Science ®Google Scholar
• Xiao, L., Zhu, X., Gillespie, A., Feng, Y., Zhou, J., Chen, X., Gao, Y., Wang, X., Ma, X., Gao, C., Xie, Y., Pan, X., Bai, Y., Xu, X., Wang, G., & Chen, R. (2021). Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: A two-phase, multicentre, randomized, double-blind clinical trial. Psychological Medicine, 51(7), 1166–1174. https://doi.org/10.1017/S0033291719004069
   PubMed Web of Science ®Google Scholar
• Yao, L., Pan, L., Qian, M., Sun, W., Gu, C., Chen, L., Tang, X., Hu, Y., Xu, L., Wei, Y., Hui, L., Liu, X., Wang, J., & Zhang, T. (2020). Tumor necrosis factor-α variations in patients with major depressive disorder before and after antidepressant treatment. Frontiers in Psychiatry, 11, 518837. https://doi.org/10.3389/fpsyt.2020.518837
   PubMed Web of Science ®Google Scholar